4//SEC Filing
Sofinnova Venture Partners IX, L.P. 4
Accession 0001104659-20-006401
CIK 0001659323other
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 7:25 PM ET
Size
11.1 KB
Accession
0001104659-20-006401
Insider Transaction Report
Form 4
Sofinnova Venture Partners IX, L.P.
10% Owner
Transactions
- Award
6.500% Exchangeable Senior Subordinated Note due 2025
2020-01-21$1750000.00/shExp: 2025-01-31→ Ordinary Shares (1,750,000 underlying)
Sofinnova Management IX, L.L.C.
10% Owner
Transactions
- Award
6.500% Exchangeable Senior Subordinated Note due 2025
2020-01-21$1750000.00/shExp: 2025-01-31→ Ordinary Shares (1,750,000 underlying)
POWELL MICHAEL
10% Owner
Transactions
- Award
6.500% Exchangeable Senior Subordinated Note due 2025
2020-01-21$1750000.00/shExp: 2025-01-31→ Ordinary Shares (1,750,000 underlying)
Footnotes (3)
- [F1]On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.
- [F2]The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms.
- [F3]The Exchangeable Note is held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any. Dr. Anand Mehra, a reporting person on the Fund's prior Section 16 filings with respect to the Company, is no longer a managing member of the GP, and accordingly, is not a reporting person on this Form 4.
Documents
Issuer
Iterum Therapeutics plc
CIK 0001659323
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001612133
Filing Metadata
- Form type
- 4
- Filed
- Jan 22, 7:00 PM ET
- Accepted
- Jan 23, 7:25 PM ET
- Size
- 11.1 KB